Understanding the epigenetic consequences of SMARCB1 loss might provide insight to oncogenesis and may help in developing therapies for a multitude of SWI/SNF mutant neoplasms [34]. SMARCB1 losses have also been described in other tumors such as renal medullary carcinoma, epithelioid sarcomas, and nerve sheath neoplasms [33]. The gene discussed is SMARCB1; the disease is neoplasm.